ClinicalTrials.gg
CompletedNCT03238482Updated Apr 6, 2018

Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

A Phase 1 interventional study of salmeterol-fluticasone and salmeterol-fluticasone in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-06.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.

Enrollment
12th of 19
64 · median 72
Started
2017
the only one that year
Phase 1
12 of 21
none open now
Registered
17th of 21
by date

Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2017, is one of 12 in phase 1, and was the 17th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Asthma by Orion Corporation, Orion Pharma as a file.
02

Study summary

The purpose of this study is to compare absorption of salmeterol and fluticasone from Salmeterol/fluticasone Easyhaler test products to the commercially available product Seretide Diskus

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion Criteria:

  1. Written (IC) obtained.
  2. Males and females, 18-60 (inclusive) years of age.
  3. Normal weight defined as (BMI) 19-30 kg/m2 (BMI = weight/height2).
  4. Weight at least 50 kg.

Main exclusion Criteria:

  1. Evidence of a cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic, endocrine, neurological or psychiatric disease.
  2. Any condition requiring regular concomitant treatment.
  3. Any clinically significant abnormal laboratory value or physical finding that in the opinion of the investigator may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  4. Known to the active substance(s) or the lactose.
  5. Pregnant or lactating females and females of not using proper .
  6. Blood donation or loss of significant amount of blood within 90 days prior to first study treatment administration.
  7. Administration of another medicinal product within 90 days prior to first study treatment administration.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    Seretide Diskus

    salmeterol-fluticasone 2 inhalations as a single dose

    Drug: salmeterol-fluticasone

  • Experimental
    Salmeterol/fluticasone Easyhaler, E

    salmeterol-fluticasone 2 inhalations as a single dose

    Drug: salmeterol-fluticasone

  • Experimental
    Salmeterol/fluticasone Easyhaler, F

    salmeterol-fluticasone 2 inhalations as a single dose

    Drug: salmeterol-fluticasone

  • Experimental
    Salmeterol/fluticasone Easyhaler, G

    salmeterol-fluticasone 2 inhalations as a single dose

    Drug: salmeterol-fluticasone

Interventions

  • Drugsalmeterol-fluticasone

    Seretide Diskus 50/250 µg/dose

  • Drugsalmeterol-fluticasone

    Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E

  • Drugsalmeterol-fluticasone

    Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F

  • Drugsalmeterol-fluticasone

    Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax) of salmeterol

    Cmax of salmeterol

    Time frame: between 0-34 hours after dosing

  2. Peak plasma concentration (Cmax) of fluticasone propionate

    Cmax of fluticasone propionate

    Time frame: between 0-34 hours after dosing

  3. Area under the plasma concentration versus time curve (AUC) of salmeterol

    AUC from time zero to the last sample with the quantifiable concentration

    Time frame: 0-34 hours after dosing

  4. Area under the plasma concentration versus time curve (AUC) of fluticasone propionate

    AUC from time zero to the last sample with the quantifiable concentration

    Time frame: 0-34 hours after dosing

  5. Truncated area under the plasma concentration versus time curve (AUC) of salmeterol

    AUC from time zero to 30 min after study treatment administration

    Time frame: 0-30 minutes after dosing

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of salmeterol

    AUC from time zero to infinity

    Time frame: 0-34 hours after dosing and extrapolation

  2. Area under the plasma concentration versus time curve (AUC) of fluticasone propionate

    AUC from time zero to infinity

    Time frame: 0-34 hours after dosing and extrapolation

  3. The time to reach the maximum concentration (tmax) of salmeterol

    tmax of salmeterol

    Time frame: 0-34 hours after dosing

  4. The time to reach the maximum concentration (tmax) of fluticasone propionate

    tmax of fluticasone propionate

    Time frame: 0-34 hours after dosing

  5. The terminal elimination half-life (t1/2) of salmeterol

    t1/2 of salmeterol

    Time frame: 0-34 hours after dosing

  6. The terminal elimination half-life (t1/2) of fluticasone propionate

    t1/2 of fluticasone propionate

    Time frame: 0-34 hours after dosing

Other outcomes

  1. Adverse events

    Adverse events

    Time frame: through study completion, an average of 6 weeks

07

Study locations

1 site
  • Clinical Pharmacology Unit, Orion Pharma
    Espoo, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Dec 2017, 4 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 4 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2017
First posted
Aug 3, 2017
StartActual
Aug 16, 2017
Primary completionActual
Dec 19, 2017
CompletionActual
Dec 19, 2017
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03238482
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Aug 16, 2017
Primary completion
Dec 19, 2017
Completion
Dec 19, 2017
Last update
Apr 6, 2018

Study contacts

Ulla Sairanen
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion